Aimee L Jackson

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi Expression profiling reveals off-target gene regulation by RNAi
    Aimee L Jackson
    Rosetta Inpharmatics LLC, 12040 115th Avenue NE, Kirkland, Washington 98034, USA
    Nat Biotechnol 21:635-7. 2003
  2. ncbi Noise amidst the silence: off-target effects of siRNAs?
    Aimee L Jackson
    Rosetta Inpharmatics LLC, 401 Terry Avenue N, Seattle, WA 98109, USA
    Trends Genet 20:521-4. 2004
  3. pmc Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity
    Aimee L Jackson
    Rosetta Inpharmatics, LLC, Seattle, WA 98109, USA
    RNA 12:1179-87. 2006
  4. pmc Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing
    Aimee L Jackson
    Rosetta Inpharmatics, LLC, Seattle, WA 98109, USA
    RNA 12:1197-205. 2006
  5. pmc MicroRNA-like off-target transcript regulation by siRNAs is species specific
    Julja Burchard
    Rosetta Inpharmatics LLC, Seattle, Washington 98109, USA
    RNA 15:308-15. 2009
  6. doi Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215
    Sara A Georges
    Rosetta Inpharmatics LLC, Seattle, Washington WA 98109, USA
    Cancer Res 68:10105-12. 2008
  7. pmc Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression
    Peter S Linsley
    Rosetta Inpharmatics, LLC, 401 Terry Ave N, Seattle, WA 98109, USA
    Mol Cell Biol 27:2240-52. 2007
  8. pmc MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression
    Irena Ivanovska
    Rosetta Inpharmatics LLC, 401 Terry Ave N, Seattle, WA 98109, USA
    Mol Cell Biol 28:2167-74. 2008
  9. pmc Myc-regulated microRNAs attenuate embryonic stem cell differentiation
    Chin Hsing Lin
    Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 4417, USA
    EMBO J 28:3157-70. 2009
  10. pmc Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions
    Steven R Bartz
    Rosetta Inpharmatics, LLC, Seattle, WA 98109, USA
    Mol Cell Biol 26:9377-86. 2006

Collaborators

Detail Information

Publications16

  1. ncbi Expression profiling reveals off-target gene regulation by RNAi
    Aimee L Jackson
    Rosetta Inpharmatics LLC, 12040 115th Avenue NE, Kirkland, Washington 98034, USA
    Nat Biotechnol 21:635-7. 2003
    ..These results demonstrate that siRNAs may cross-react with targets of limited sequence similarity...
  2. ncbi Noise amidst the silence: off-target effects of siRNAs?
    Aimee L Jackson
    Rosetta Inpharmatics LLC, 401 Terry Avenue N, Seattle, WA 98109, USA
    Trends Genet 20:521-4. 2004
    ..In the meantime, caution is warranted in interpreting gene function and phenotypes resulting from RNAi experiments...
  3. pmc Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity
    Aimee L Jackson
    Rosetta Inpharmatics, LLC, Seattle, WA 98109, USA
    RNA 12:1179-87. 2006
    ..Thus, short stretches of sequence complementarity to the siRNA or shRNA seed region are key to the silencing of unintended transcripts...
  4. pmc Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing
    Aimee L Jackson
    Rosetta Inpharmatics, LLC, Seattle, WA 98109, USA
    RNA 12:1197-205. 2006
    ....
  5. pmc MicroRNA-like off-target transcript regulation by siRNAs is species specific
    Julja Burchard
    Rosetta Inpharmatics LLC, Seattle, Washington 98109, USA
    RNA 15:308-15. 2009
    ..Therefore, siRNA therapeutics may trigger microRNA-like silencing of many unintended targets in vivo, and the potential toxicities caused by these off-target gene regulations cannot be accurately assessed in rodent models...
  6. doi Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215
    Sara A Georges
    Rosetta Inpharmatics LLC, Seattle, Washington WA 98109, USA
    Cancer Res 68:10105-12. 2008
    ..Our results showing a role for miR-192/215 in cell proliferation combined with recent observations that these miRNAs are underexpressed in primary cancers support the idea that miR-192 and miR-215 function as tumor suppressors...
  7. pmc Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression
    Peter S Linsley
    Rosetta Inpharmatics, LLC, 401 Terry Ave N, Seattle, WA 98109, USA
    Mol Cell Biol 27:2240-52. 2007
    ..Simultaneous silencing of these genes was more effective at blocking cell cycle progression than disruption of the individual genes. Thus, miR-16 coordinately regulates targets that may act in concert to control cell cycle progression...
  8. pmc MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression
    Irena Ivanovska
    Rosetta Inpharmatics LLC, 401 Terry Ave N, Seattle, WA 98109, USA
    Mol Cell Biol 28:2167-74. 2008
    ..We also show that miR-106b overrides a doxorubicin-induced DNA damage checkpoint. Thus, miR-106b family members contribute to tumor cell proliferation in part by regulating cell cycle progression and by modulating checkpoint functions...
  9. pmc Myc-regulated microRNAs attenuate embryonic stem cell differentiation
    Chin Hsing Lin
    Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 4417, USA
    EMBO J 28:3157-70. 2009
    ..In contrast, knockdown of the endogenous miRNAs accelerate differentiation. Our data show that in ES cells c-Myc acts, in part, through a subset of miRNAs to attenuate differentiation...
  10. pmc Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions
    Steven R Bartz
    Rosetta Inpharmatics, LLC, Seattle, WA 98109, USA
    Mol Cell Biol 26:9377-86. 2006
    ..Thus, tumor cells having disruptions in BRCA1/2 network genes and TP53 together are more sensitive to cisplatin than cells with either disruption alone...
  11. ncbi How will RNAi facilitate drug development?
    Steven Bartz
    Rosetta Inpharmatics, LLC, a wholly owned subsidiary of Merck and Co, Inc, 401 Terry Avenue North, Seattle, WA 98109, USA
    Sci STKE 2005:pe39. 2005
    ..Here, we discuss the potential impact of RNAi screens on target identification and validation and consider issues that warrant caution when interpreting RNAi screening results...
  12. ncbi A microRNA component of the p53 tumour suppressor network
    Lin He
    Watson School of Biological Sciences, Howard Hughes Medical Institute, Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, New York 11724, USA
    Nature 447:1130-4. 2007
    ..The p53 network suppresses tumour formation through the coordinated activation of multiple transcriptional targets, and miR-34 may act in concert with other effectors to inhibit inappropriate cell proliferation...
  13. ncbi Genome-scale RNAi profiling of cell division in human tissue culture cells
    Ralf Kittler
    Max Planck Institute for Molecular Cell Biology and Genetics, Pfotenhauerstrasse 108, D 01307 Dresden, Germany
    Nat Cell Biol 9:1401-12. 2007
    ..Our work provides an experimental framework from which the systematic analysis of novel genes necessary for cell division in human cells can begin...
  14. ncbi Genome-wide resources of endoribonuclease-prepared short interfering RNAs for specific loss-of-function studies
    Ralf Kittler
    Max Planck Institute for Molecular Cell Biology and Genetics, Pfotenhauerstrasse 108, D 01307 Dresden, Germany
    Nat Methods 4:337-44. 2007
    ..Hence, the presented esiRNA libraries offer an efficient, cost-effective and specific alternative to presently available mammalian RNAi resources...
  15. ncbi Minimizing the risk of reporting false positives in large-scale RNAi screens
    Christophe J Echeverri
    Cenix BioScience GmbH, Tatzberg 47, Dresden, 10307, Germany
    Nat Methods 3:777-9. 2006
    ....